81 related articles for article (PubMed ID: 15825052)
1. Anti-interleukin-12 antibody treatment for Crohn disease: potential risk of invasive disease due to mycobacteria and salmonellae infection.
MacLennan C; Lammas DA; Kumararatne DS
Clin Infect Dis; 2005 May; 40(9):1381-2. PubMed ID: 15825052
[No Abstract] [Full Text] [Related]
2. High risk of infectious disease caused by salmonellae and mycobacteria infections in patients with Crohn disease treated with anti-interleukin-12 antibody.
Fieschi C; Allez M; Casanova JL
Clin Infect Dis; 2005 May; 40(9):1381. PubMed ID: 15825051
[No Abstract] [Full Text] [Related]
3. Anti-interleukin-12 antibody for active Crohn's disease.
Orenstein R
N Engl J Med; 2005 Feb; 352(6):627-8; author reply 627-8. PubMed ID: 15703432
[No Abstract] [Full Text] [Related]
4. Anti-interleukin-12 antibody for active Crohn's disease.
Kolls JK; Zhang Z
N Engl J Med; 2005 Feb; 352(6):627-8; author reply 627-8. PubMed ID: 15706644
[No Abstract] [Full Text] [Related]
5. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
6. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy.
Bowman EP; Chackerian AA; Cua DJ
Curr Opin Infect Dis; 2006 Jun; 19(3):245-52. PubMed ID: 16645485
[TBL] [Abstract][Full Text] [Related]
7. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
[TBL] [Abstract][Full Text] [Related]
8. Antimycobacterial therapy in Crohn's disease: game over?
Peyrin-Biroulet L; Neut C; Colombel JF
Gastroenterology; 2007 Jun; 132(7):2594-8. PubMed ID: 17570230
[No Abstract] [Full Text] [Related]
9. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody.
Kohara MM; Blum RN
Clin Infect Dis; 2006 Mar; 42(5):733-4. PubMed ID: 16447129
[No Abstract] [Full Text] [Related]
10. Fatal disseminated cytomegalovirus infection associated with infliximab and 6-mercaptopurine therapy in a child with Crohn disease.
Pickering O; Weinstein T; Rubin LG
Pediatr Infect Dis J; 2009 Jun; 28(6):556. PubMed ID: 19483533
[No Abstract] [Full Text] [Related]
11. Infliximab-induced palmoplantar pustulosis in a patient with crohn disease.
Sladden MJ; Clarke PJ; Wettenhall J
Arch Dermatol; 2007 Nov; 143(11):1449. PubMed ID: 18025378
[No Abstract] [Full Text] [Related]
12. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
13. Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.
Fallon JC; Patchett S; Gulmann C; Murphy GM
Clin Exp Dermatol; 2008 Jan; 33(1):43-5. PubMed ID: 17983451
[TBL] [Abstract][Full Text] [Related]
14. [Infliximab-induced pustular psoriasis in a patient with Crohn's disease].
Monteagudo Sánchez B; Cabanillas M; Ortiz-Marin S; Gallego-Ojea JC
Gastroenterol Hepatol; 2009 Mar; 32(3):175-6. PubMed ID: 19233516
[No Abstract] [Full Text] [Related]
15. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
Sorrentino D; Terrosu G; Vadalà S; Avellini C
Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
[No Abstract] [Full Text] [Related]
16. Remicade approved for children with Crohn's disease.
FDA Consum; 2006; 40(4):6. PubMed ID: 17245830
[No Abstract] [Full Text] [Related]
17. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab.
Silbermintz A; Krishnan S; Banquet A; Markowitz J
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):324-6. PubMed ID: 16540804
[No Abstract] [Full Text] [Related]
18. Balancing the risks and benefits of prolonged use of infliximab.
Schölmerich J
Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
[TBL] [Abstract][Full Text] [Related]
20. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab.
Francolla KA; Altman A; Sylvester FA
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):193-5. PubMed ID: 18664872
[No Abstract] [Full Text] [Related]
[Next] [New Search]
